Drugs FDA-approved for hematology / oncology in 2020: ‘Game-changing’ and ‘niche’ indications

Thursday, June 18, 2020

The Food and Drug Administration has approved dozens of drugs for new hematology/oncology indications this year. Host David Henry, MD, was joined by David Mintzer, MD, and other colleagues at Penn Medicine in Philadelphia – Justine Cohen, DO, and Ingrid Kohut, DO – to discuss some of these approvals.

Dr. Mintzer reviewed:

  • The “game-changing” approval of niraparib (Zejula) in advanced ovarian, fallopian tube, or primary peritoneal cancer.
  • The “exciting” approval of sacituzumab govitecan-hziy (Trodelvy) in metastatic triple-negative breast cancer.
  • The “COVID-relevant” approval of a new dosing regimen for pembrolizumab (Keytruda) – 400 mg every 6 weeks – across all approved adult indications.
  • The “niche” approval of mitomycin (Jelmyto) for adults with low-grade upper tract urothelial cancer.
  • And several other approvals the FDA granted this year.

Details on all approvals are available on the FDA website.

* * *


Dr. Henry and all guests reported having no relevant disclosures.

* * *

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: [email protected]

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.